[ad_1]
The candidate vaccine developed at the University of Oxford is safe and 70 percent effective, according to an article published in the acclaimed medical journal The Lancet.
The article shows that the degree of protection is on average 70 percent; 90 percent in cases where people were vaccinated for the first time with half doses and 62 percent effective when subjects received two full doses.
– Insurance
More than 20,000 volunteers participated in the AstraZeneca study, which is being developed in collaboration with the University of Oxford, the UK, Brazil and South Africa.
– The vaccine was found to be safe, only three of the 23,745 participants had serious side effects that were possibly related to the vaccine over a median period of 3.4 months, The Lancet writes in a press release.
also read
Study: Oxford vaccine is 70 percent effective
In of these were in the vaccine group, in in the control group, while it is not revealed to which group the third person belongs. All have recovered or are on the road to recovery and are still in the study, it is further stated.
This is the first peer review of this phase three study.
But where long the vaccine works, it is not known since the first clinical trials did not begin until April of this year.
– Good sign
– When you compare the side effects in the group that received the vaccine with those of the group that received placebo and there is no difference, it is basically a good sign, says Steinar Madsen, medical director of the Norwegian Medicines Agency, to VG.
It states that the authorities will especially consider side effects when they now have to review all the data from the various studies before possibly approving a vaccine for use in Norway.
– But what we’ve seen from different vaccines is that there are a small number of serious side effects, says Madsen.
Read more about the candidate vaccine here:
By mistake, many AstraZeneca study participants were given half a dose at the first vaccination. However, this proved to be more effective than giving the full dose twice.
It has made Madsen and others at the Norwegian Medicines Agency scratch their heads.
– It is conceivable that a first full dose provides such a strong immune response that it also works against the vaccine when you receive the next dose. It may be better to just “tickle” the immune system with a lower dose first, says Madsen.
On Tuesday there was also good news for the Pfizer vaccine. Provides good protection against COVID-19 within ten days of the first dose, a new FDA report shows.